# Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy

> **NCT07663422** · PHASE2 · RECRUITING · sponsor: **Fox Chase Cancer Center** · enrollment: 31 (estimated)

## Conditions studied

- Immune-mediated Hepatitis
- Immune-related Adverse Event

## Interventions

- **DRUG:** Mycophenolate Mofetil plus prednisone

## Key facts

- **NCT ID:** NCT07663422
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-23
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-09-30
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2026-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07663422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07663422, "Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT07663422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*